Autolus Therapeutics

• Capital Increase of 58,333,333 ADSs, representing 58,333,333 ordinary shares and corresponding to c. 34% of Autolus’ outstanding capital prior to the Capital Increase, generating gross proceeds of USD 350 million
• The placement price of USD 6.00 per ADS represents a discount of 5.1% vis-à-vis the last closing price
• The transaction was launched on the back of a strategic partnership with BioNTech whereby BioNTech receives access to Autolus’ clinical and commercial supply infrastructure, an exclusive license agreement for certain of Autolus' proprietary binders as well as royalties on future obe-cel sales
• Autolus intends to use the proceeds to advance the clinical development and manufacturing activities of its obe-cel program and fund development of its commercial infrastructure
• Van Lanschot Kempen is proud to have assisted Autolus as a repeat client in raising capital following our previous involvement in Autolus’ February 2021 Capital Increase

Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies, solid tumours and autoimmune diseases

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Financial Adviser to Galapagos in the EUR 170 million sale of its Jyseleca business to Alfasigma
• Sole Financial Adviser to Zealand Pharma in securing a EUR 90 million venture debt facility from the European Investment Bank
• Joint Global Coordinator & Joint Bookrunner in the SEK 59 million Capital Increase by Cantargia
• Joint Global Coordinator & Joint Bookrunner in the NOK 505 million Capital Increase by Nykode Therapeutics
• Sole Financial Adviser in the SEK 120 million Structured Equity transaction by SynAct Pharma
• Lead Manager in the USD 173 million Capital Increase by Merus
• Lead Manager in the USD 1.3 billion Capital Increase by argenx
• Joint Bookrunner in the SEK 500m Capital Increase by Vicore Pharma
• Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors
• Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Adviser & Placement Agent in the Merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE